Bob Durkin, AGG Food & Drug co-chair and member of the Dietary Supplements team, was quoted in a June 24, 2023, Natural Products Insider article discussing the potential impact of FDA’s proposed harm-reduction framework for CBD-containing supplement products.
In the article, Bob stated that the framework is “largely redundant to the risk-reduction framework” in effect for dietary supplement products. He also noted that FDA has authority to require clear supplement labels under its current good manufacturing practices rule (21 C.F.R. 111) and could impose CBD content limits based on the adulteration standard in the Dietary Supplement Health and Education Act of 1994 (“DSHEA”) related to products that pose “a significant or unreasonable risk of illness or injury.”
To read the full article, please click here.